Canaccord Genuity Reiterates a 'Buy' on Cepheid (CPHD); Q4 Results Demonstrate Strong Hospital Interest in MDx
Tweet Send to a Friend
Canaccord Genuity reiterates a 'Buy' on Cepheid (NASDAQ: CPHD), raises PT from $27 to $30.
Canaccord analyst says, "We reiterate ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Canaccord analyst says, "We reiterate ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
